Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High vs Moderate Dose Rosuvastatin Post-PCI
NCT04923152Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jan 2020
- Primary completion
- Jan 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of rosuvastatin in angina pectoris (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Major Adverse Cardiovascular Events at 1 year and High-Sensitivity C-Reactive Protein at 1 year. Started Jan 2020; status: completed.
02
Drugs
rosuvastatin
03
Conditions
angina pectoris
Beyond the preview
Go deeper on NCT04923152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04923152.